The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Neil Martin1 · Joyce Davidson1 · Catriona Anderson1 · Alessandro Consolaro2,3 · Francesca Bovis2 · Nicolino Ruperto2 · For the Paediatric Rheumatology International Trials Organisation (PRINTO)

Received: 22 December 2017 / Accepted: 11 January 2018 © The Author(s) 2018. This article is an open access publication

Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the British English language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 100 JIA patients (7.0% systemic, 38.0% oligoarticular, 27.0% RF negative polyarthritis, 28% other categories) and 100 healthy children, were enrolled at the Royal Hospital for Sick Children in Glasgow. The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the British English version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.

Keywords  Juvenile idiopathic arthritis · Disease status · Functional ability · Health-related quality of life · JAMAR

Introduction
The aim of the present study was to cross-culturally adapt and validate the British English parent, child/adult version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) [1] in patients with juvenile idiopathic arthritis (JIA). The JAMAR assesses the most relevant parent/patient-reported outcomes in JIA, including overall

Francesca Bovis
francescabovis@gaslini.org

1 Rheumatology Department, Royal Hospital for Children, 1345 Govan Road, Glasgow G51 4TF, UK
2 Clinica Pediatrica e Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO), Istituto Giannina Gaslini, Via Gaslini 5, 16147 Genoa, Italy
3 Dipartimento di Pediatria, Università di Genova, Genoa, Italy
well-being, functional status, health-related quality of life (HRQoL), pain, morning stiffness, disease activity/status/course, articular and extra-articular involvement, drug-related side effects/compliance and satisfaction with illness outcome.

This project was part of a larger multinational study conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) [2] aimed to evaluate the Epidemiology, Outcome and Treatment of Childhood Arthritis (EPOCA) in different geographic areas [3].

We report herein the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the British English language.

Materials and methods

The methodology employed has been described in detail in the introductory paper of the supplement [4]. In brief, it was a cross-sectional study of JIA children, classified according to the ILAR criteria [5, 6] and enrolled from February 2013 to July 2013. Children were recruited after Ethics Committee approval and consent from at least one parent.

The JAMAR

The JAMAR [1] includes the following 15 sections:

1. Assessment of physical function (PF) using 15-items in which the ability of the child to perform each task is scored as follows: 0 = without difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do and not applicable if it was not possible to answer the question or the patient was unable to perform the task due to their young age or to reasons other than JIA. The total PF score ranges from 0 to 45 and has 3 components: PF-lower limbs (PF-LL); PF-hand and wrist (PF-HW) and PF-upper segment (PF-US) each scoring from 0 to 15 [7]. Higher scores indicating higher degree of disability [8–10].

2. Rating of the intensity of the patient’s pain on a 21-numbered circle Visual Analogue Scale (VAS) [11].

3. Assessment of the presence of joint pain or swelling (present/absent for each joint).

4. Assessment of morning stiffness (present/absent).

5. Assessment of extra-articular symptoms (fever and rash) (present/absent).

6. Rating of the level of disease activity on a 21-circle VAS.

7. Rating of disease status at the time of the visit (categorical scale).

8. Rating of disease course from previous visit (categorical scale).

9. Checklist of the medications the patient is taking (list of choices).

10. Checklist of side effects of medications.

11. Report of difficulties with medication administration (list of items).

12. Report of school/university/work problems caused by the disease (list of items).

13. Assessment of HRQoL, through the Physical Health (PhH), and Psychosocial Health (PsH) subscales (five items each) and a total score. The four-point Likert response, referring to the prior month, are ‘never’ (score = 0), ‘sometimes’ (score = 1), ‘most of the time’ (score = 2) and ‘all the time’ (score = 3). A ‘not assessable’ column was included in the parent version of the questionnaire to designate questions that cannot be answered because of developmental immaturity. The total HRQoL score ranges from 0 to 30, with higher scores indicating worse HRQoL. A separate score for PhH and PsH (range 0–15) can be calculated [12–14].

14. Rating of the patient’s overall well-being on a 21-numbered circle VAS.

15. A question about satisfaction with the outcome of the illness (yes/no) [15].

The JAMAR is available in three versions, one for parent proxy-report (child’s age 2–18), one for child self-report, with the suggested age range of 7–18 years, and one for adults.

Cross-cultural adaptation and validation

The standard English version of JAMAR was defined in occasion of three different consensus meetings where three independent professional translators agreed on a unique standard English translation of the first Italian draft of JAMAR. The three independent translators were selected on the basis of their native language, their age and sex. This standard English version was spread out through the PRINTO national coordinators who had agreed to participate. Reading comprehension and understanding of the text was tested in a probe sample of ten JIA parents and ten patients.

Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents.

The statistical validation phase explored the descriptive statistics and the psychometric issues [16]. In particular, we evaluated the following validity components: the first Likert assumption [mean and standard deviation (SD) equivalence];
the second Likert assumption or equal items-scale correlations (Pearson $r$; all items within a scale should contribute equally to the total score); third Likert assumption (item internal consistency or linearity for which each item of a scale should be linearly related to the total score that is 90% of the items should have Pearson $r \geq 0.4$); floor/ceiling effects (frequency of items at lower and higher extremes of the scales, respectively); internal consistency, measured by the Cronbach’s alpha, interscale correlation (the correlation between two scales should be lower than their reliability coefficients, as measured by Cronbach’s alpha); test–retest reliability or intra-class correlation coefficient (reproducibility of the JAMAR repeated after 1 or 2 weeks); and construct validity in its two components: the convergent or external validity which examines the correlation of the JAMAR subscales with the six JIA core set variables, with the addition of the parent assessment of disease activity and pain by the Spearman’s correlation coefficients ($r$) [17] and the discriminant validity, which assesses whether the JAMAR discriminates between the different JIA categories and healthy children [18].

Quantitative data were reported as medians with 1st and 3rd quartiles and categorical data as absolute frequencies and percentages.

The complete British English parent and patient versions of the JAMAR are available upon request to PRINTO.

Results

Cross-cultural adaptation

In the probe technique analysis, all 123 lines were understood by at least 80% of the parents (median 100%; range 90–100%). All the 120 lines of the patient version of the JAMAR were understood by at least 80% of the children (median 100%; range 90–100%). The texts of the parent JAMAR and of the child JAMAR were unmodified after the probe technique.

Probe technique

In the probe technique analysis, all the 123 lines of the parent version of the JAMAR were understood by at least 80% of the 10 parents tested (median 100%; range 90–100%). For the 120 lines of the patient version of the JAMAR, all the lines were understood by at least 80% of the children (median 100%; range 90–100%). The texts of the parent JAMAR and of the child JAMAR were unmodified after the probe technique.

Demographic and clinical characteristics of the subjects

A total of 100 JIA patients and 100 healthy children (total of 200 subjects), were enrolled at the Royal Hospital for Sick Children in Glasgow.

In the 100 JIA subjects, the JIA categories were 7.0% with systemic arthritis, 38.0% with oligoarthritis, 27.0% with RF negative polyarthritis, 1.0% with RF positive polyarthritis, 5.0% with psoriatic arthritis, 9.0% with Enthesitis related arthritis and 13.0% with undifferentiated arthritis (Table 1).

A total of 177/200 (88.5%) subjects had the parent version of the JAMAR completed by a parent (97 from parents of JIA patients and 80 from parents of healthy children). The JAMAR was completed by 133/177 (75.1%) mothers and 44/177 (24.9%) fathers. The child version of the JAMAR was completed by 112/200 (56.0%) children age 6.7 or older. Also patients younger than 7 years old, capable to assess their personal condition and able to read and write, were asked to fill in the patient version of the questionnaire.

Discriminant validity

The JAMAR results are presented in Table 1, including the scores [median (1st–3rd quartile)] obtained for the PF, the PhH, the PsH subscales and total score of the HRQoL scales. The JAMAR components discriminated well between healthy subjects and JIA patients.

In summary, the JAMAR revealed that JIA patients had a greater level of disability and pain, as well as a lower HRQoL than their healthy peers.

Psychometric issues

The main psychometric properties of both parent and child versions of the JAMAR are reported in Table 2. The following results section refers mainly to the parent’s version findings, unless otherwise specified.

Descriptive statistics (first Likert assumption)

There were no missing results for all JAMAR items, since data were collected through a web-based system that did not allow to skip answers and input of null values. The response pattern for both PF and HRQoL was positively skewed toward normal functional ability and normal HRQoL. All response choices were used for the different HRQoL items,
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 100 JIA patients

|                          | Systemic (N=7) | Oligoarthritis (N=38) | RF− polyarthrits (N=27) | RF+ polyarthrits (N=1) | Psoriatic arthritis (N=5) | Enthesitis related arthritis (N=13) | Undifferentiated arthritis (N=9) | All JIA patients (N=100) | Healthy (N=100) |
|--------------------------|----------------|-----------------------|-------------------------|------------------------|---------------------------|--------------------------------------|----------------------------------|--------------------------|------------------|
| Female                   | 4 (57.1%)      | 23 (60.5%)            | 22 (81.5%)              | 1 (100%)               | 3 (60%)                   | 4 (44.4%)                           | 8 (61.5%)                       | 65 (65%)                 | 53 (53%)         |
| Age at visit             | 11.9 (6.8–12.9)| 9.9 (5-12.8)          | 11.9 (9.9–15.8)         | 17.9 (17.9–19)         | 12.8 (11.9–13.9)          | 14.9 (10-15.8)                      | 11.9 (10.8–12.9)               | 11.8 (8.8–14.4)      | 9.8 (6.1–14)* |
| Age at onset             | 7.1 (1.4–8.9)  | 3.2 (2.3–6.8)         | 5.8 (2.6–9.3)           | 13.2 (13.2–13.2)       | 9.8 (3.4–10.5)            | 9.8 (3.4–11.1)                      | 4 (2.6–5.5)                    | 5.6 (2.4–9)*     |
| Disease duration         | 4.8 (3.1–5.5)  | 3.3 (1.3–7)           | 5.1 (2–9.5)             | 4.7 (4.7–4.7)          | 3.5 (2.9–7.5)             | 3.7 (1.7–4.9)                       | 6.3 (3.2–9.3)                  | 4.6 (1.8–7.6)       |
| ESR                      | 5 (1–5)        | 8 (5–12)              | 8 (5–12)                | 6 (6–6)                | 12 (10–14)                | 8 (8–9)                             | 6 (4–15)                        | 8 (5–12)         |
| MD VAS (0–10 cm)         | 0 (0–1)        | 0 (0–2)               | 1 (0–2)                 | 0 (0–0)                | 0 (0–0)                   | 0 (0–2)                             | 0 (0–2)                         | 0 (0–2)        |
| No. swollen joints       | 0 (0–0)        | 0 (0–1)               | 0 (0–2)                 | 0 (0–0)                | 0 (0–0)                   | 0 (0–2)                             | 0 (0–2)                         | 0 (0–2)        |
| No. joints with pain     | 0 (0–0)        | 0 (0–1)               | 0 (0–2)                 | 0 (0–0)                | 0 (0–0)                   | 0 (0–2)                             | 0 (0–2)                         | 0 (0–2)        |
| No. joints with LOM      | 0 (0–1)        | 1 (0–2)               | 1 (0–3)                 | 1 (1–1)                | 0 (0–1)                   | 2 (0–4)                             | 2 (0–4)                         | 1 (0–3)        |
| No. active joints        | 0 (0–1)        | 0 (0–2)               | 0 (0–2)                 | 0 (0–0)                | 0 (0–0)                   | 1 (0–2)                             | 0 (0–0)                         | 0 (0–1)        |
| Active systemic features | 2 (28.6%)      | 0 (0%)                | 0 (0%)                  | 0 (0%)                 | 0 (0%)                    | 0 (0%)                              | 2 (2%)                          | 0 (0–1.5)     |
| ANA status               | 0 (0%)         | 3 (7.9%)              | 7 (25.9%)               | 0 (0%)                 | 0 (0%)                    | 0 (0%)                              | 1 (7.7%)                        | 11 (11%)      |
| Uveitis                  | 0 (0%)         | 7/37 (18.9%)          | 5 (18.5%)               | 0 (0%)                 | 1 (20%)                   | 0 (0%)                              | 1 (7.7%)                        | 14 (14.1%)    |
| PF total score           | 1 (0–4)        | 1 (0–5)               | 3 (1–6)                 | 2 (2–6)                | 5 (2–11)                  | 2 (0–3)                             | 2 (0–5)*                        | 0 (0–0)*       |
| Pain VAS                 | 0.5 (0-3.5)    | 1.8 (0-3.5)           | 2.5 (0.5–5.5)           | 5.5 (0–7)              | 4 (3–7)                   | 1.5 (0–4)                           | 2.5 (0.5–5)                     | 0 (0–0)*       |
| Disease activity VAS     | 1.5 (0–3)      | 2 (0–4)               | 2.5 (0.5–5)             | 5 (0.5–5)              | 6 (3.5–6.5)               | 1.5 (0–7)                           | 2 (0–5)                         | 2 (0–5)       |
| Well-being VAS           | 1.5 (0-3.5)    | 1 (0–3)               | 3 (1–5)                 | 3 (0–7)                | 3 (1–7)                   | 0.5 (0–4)                           | 1.5 (0–5)                       | 3 (0–7)        |
| HRQoL PH                 | 1 (1–4)        | 3 (0–5)               | 5 (3–7)                 | 4 (4–6)                | 5 (4–8)                   | 2 (1–4)                             | 4 (1–6)*                        | 0 (0–0)*       |
| HRQoL PsH                | 3 (0–3)        | 1 (0–4)               | 3 (2–5)                 | 1 (0–5)                | 3 (2–4)                   | 2 (0–2)                             | 2 (0–4)                         | 0 (0–0)*       |
| HRQoL total score        | 4 (1–10)       | 4 (1–10)              | 8 (6–11)                | 5 (4–11)               | 9 (5–10)                  | 4 (1–7)                             | 6 (2–10)                        | 0 (0–1)*       |
| Pain/swell. in > 1 joint | 2 (28.6%)      | 22 (57.9%)            | 16/25 (64%)             | 3 (60%)                | 8 (88.9%)                 | 8 (61.5%)                           | 59/97                           | 4 (5%)*        |
| Morning stiffness > 15 min | 3 (42.9%)   | 14 (36.8%)            | 16/25 (64%)             | 3 (60%)                | 6 (66.7%)                 | 2 (15.4%)                           | 44/97                           | 0 (0%)*        |
| Subjective remission     | 4 (57.1%)      | 25 (65.8%)            | 19/25 (76%)             | 3 (60%)                | 8 (88.9%)                 | 8 (61.5%)                           | 67/97                           | 69 (69.1%)     |
| In treatment             | 7 (100%)       | 25 (65.8%)            | 24/25 (96%)             | 5 (100%)               | 7 (77.8%)                 | 9 (69.2%)                           | 77/97                           | 79 (79.4%)     |
| Reporting side effects   | 3/7 (42.9%)    | 5/25 (20%)            | 15/25 (62.5%)           | 4 (80%)                | 4/7 (51.1%)               | 39 (33.3%)                          | 34/77                           | 44 (44.2%)     |
| Taking medication regularly | 6/7 (85.7%) | 24/25 (96%)           | 21/24 (87.5%)           | 5 (100%)               | 6/7 (85.7%)               | 8/9 (88.9%)                         | 70/77                           | 90 (90.9%)     |
| With problems attending school | 2/4 (50%) | 4/18 (22.9%)          | 10/19 (52.6%)           | 1/2 (50%)              | 2/6 (33.3%)               | 2/7 (28.6%)                         | 21 (37.5%)                      | 0 (0%)*        |
| Satisfied with disease outcome | 7 (100%) | 27 (71.1%)            | 19/25 (76%)             | 5 (100%)               | 4 (44.4%)                 | 9 (60.2%)                           | 71/97                           | 73 (73.2%)     |

Data related to the JAMAR refers to the 97 JIA patients and to the 80 healthy subjects for whom the questionnaire has been completed by the parents.

*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue scale (score 0–10; 0 = no activity; 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15).

p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, *p < 0.0001
whereas a reduced number of response choices was used for all the PF items except for items 1, 2, 3, 4 and 5.

The mean and SD of the items within a scale were roughly equivalent for the PF and for the HRQoL items, except for HRQoL items 1 and 8 (data not shown). The median number of items marked as not applicable was 0% (0–0%) for the PF and 1% (0–3%) for the HRQoL.

**Floor and ceiling effect**

The median floor effect was 79.0% (69.0–87.0%) for the PF items, 44.0% (32.0–48.0%) for the HRQoL PhH items, and 54.0% (51.0–55.0%) for the HRQoL PsH items. The median ceiling effect was 0% (0–1.0%) for the PF items, 5.0% (0–5.0%) for the HRQoL PhH items, and 1.0% (1–2.0%) for the HRQoL PsH items. The median floor effect was 24.0% for the pain VAS, 27.0% for the disease activity VAS and

### Table 2 Main psychometric characteristics between the parent and child version of the JAMAR

| Missing values (1st–3rd quartiles) | Parent \((N=97/177)\) | Child \((N=71/112)\) |
|-----------------------------------|------------------------|-----------------------|
| No missing values                 | No missing values      |
| **Floor effect, median**          |                        |                        |
| PF                                | 79.0%                  | 56.0%                 |
| HRQoL PhH                         | 44.0%                  | 30.0%                 |
| HRQoL PsH                         | 54.0%                  | 41.0%                 |
| Pain VAS                          | 24.0%                  | 13.0%                 |
| Disease activity VAS              | 27.0%                  | 11.0%                 |
| Well-being VAS                    | 31.0%                  | 17.0%                 |
| **Ceiling effect, median**        |                        |                        |
| PF                                | 0.0%                   | 0.0%                  |
| HRQoL PhH                         | 5.0%                   | 2.0%                  |
| HRQoL PsH                         | 1.0%                   | 2.0%                  |
| Pain VAS                          | 0.0%                   | 1.0%                  |
| Disease activity VAS              | 0.0%                   | 0.0%                  |
| Well-being VAS                    | 0.0%                   | 1.0%                  |
| **Items with equivalent item-scale correlation** | 87% for PF, 90% for HRQoL | 87% for PF, 80% for HRQoL |
| **Items with items-scale correlation ≥ 0.4** | 100% for PF, 100% for HRQoL | 93% for PF, 100% for HRQoL |
| **Cronbach's alpha**              |                        |                        |
| PF-LL                             | 0.87                   | 0.86                  |
| PF-HW                             | 0.85                   | 0.85                  |
| PF-US                             | 0.82                   | 0.74                  |
| HRQoL-PhH                         | 0.88                   | 0.86                  |
| HRQoL-PsH                         | 0.82                   | 0.81                  |
| **Items with item-scale correlation lower than the Cronbach alpha** | 100% for PF, 100% for HRQoL | 100% for PF, 100% for HRQoL |
| **Test–retest intraclass correlation** |                        |                        |
| PF total score                    | 0.95                   | 0.97                  |
| HRQoL-PhH                         | 0.91                   | 0.92                  |
| HRQoL-PsH                         | 0.99                   | 0.88                  |
| **Spearman’s correlation with JIA core-set variables, median** |                        |                        |
| PF                                | 0.4                    | 0.3                   |
| HRQoL PhH                         | 0.5                    | 0.4                   |
| HRQoL PsH                         | 0.3                    | 0.2                   |
| Pain VAS                          | 0.4                    | 0.5                   |
| Disease activity VAS              | 0.4                    | 0.4                   |
| Well-being VAS                    | 0.4                    | 0.5                   |

*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, *JIA* juvenile idiopathic arthritis, VAS Visual Analogue Scale, *PF* physical function, *HRQoL* Health-Related Quality of Life, *PhH* Physical Health, *PsH* Psychosocial Health, *PF-LL* PF-lower limbs, *PF-HW* PF-hand and wrist, *PF-US* PF-upper segment
31.0% for the well-being VAS. The median ceiling effect was 0% for the pain VAS, 0% for the disease activity VAS and 0% for the well-being VAS.

**Equal items-scale correlations (second Likert assumption)**

Pearson items-scale correlations corrected for overlap were roughly equivalent for items within a scale for 87% of the PF items, with the exception of PF items 11 and 15, and for 90% of the HRQoL items, with the exception of item 1.

**Items internal consistency (third Likert assumption)**

Pearson items-scale correlations were ≥ 0.4 for 100% of items of the PF and 100% of items of the HRQoL.

**Cronbach’s alpha internal consistency**

Cronbach’s alpha was 0.87 for PF-LL, 0.85 for PF-HW, 0.82 for PF-US. Cronbach’s alpha was 0.88 for HRQoL-PhH and 0.82 for HRQoL-PsH.

**Interscale correlation**

The Pearson correlation of each item of the PF and the HRQoL with all items included in the remaining scales of the questionnaires was lower than the Cronbach’s alpha.

**Test–retest reliability**

Reliability was assessed in eight JIA patients, by re-administering both versions (parent and child) of the JAMAR after a median of 7 days (7–7 days). The intraclass correlation coefficients (ICC) for the PF total score showed an almost perfect reproducibility (ICC 0.95). The ICC for the HRQoL PhH and for the HRQoL PsH scores showed an almost perfect reproducibility (ICC 0.91 and 0.99, respectively).

**Convergent validity**

The Spearman’s correlation of the PF total score with the JIA core set of outcome variables ranged from 0.3 to 0.7 (median 0.4). The PF total score best correlation was observed with the parent assessment of pain ($r = 0.7$, $p < 0.001$). For the HRQoL, the median correlation of the PhH with the JIA core set of outcome variables ranged from 0.3 to 0.7 (median 0.5), whereas for the PsH ranged from 0.2 to 0.6 (median 0.3). The PhH showed the best correlation with the parent’s assessment of pain ($r = 0.8$, $p < 0.001$) and the PsH with the parent global assessment of well-being ($r = 0.7$, $p < 0.001$). The median correlations between the pain VAS, the well-being VAS, and the disease activity VAS and the physician-centred and laboratory measures were 0.4 (range 0.3–0.5).

**Discussion**

The British English version of the JAMAR was cross-culturally adapted from the original standard English version, without performing the forward and backward translations. The PRINTO National Coordinator in UK revised the standard English original, adapted it to British English and administered it to a probe sample of ten JIA parents and ten patients. According to the results of the validation analysis, the British English parent and patient versions of the JAMAR possess satisfactory psychometric properties. The disease-specific components of the questionnaire discriminated well between patients with JIA and healthy controls. The PF total score and the PhH score proved to discriminate between the different JIA subtypes with children with Enthesitis related arthritis having a higher degree of disability and a lower quality of life.

Psychometric performances were good for all domains of the JAMAR and the overall internal consistency was good for all the domains.

In the external validity evaluation, the Spearman’s correlations of the PF and HRQoL scores with JIA core set parameters ranged from weak to moderate.

The statistical performances of the child version of the JAMAR are very similar, although slightly poorer, to those obtained by the parent version, which suggests that children are reliable reporters of their disease and health status.

The JAMAR is aimed to evaluate the side effects of medications and school attendance, which are other dimensions of daily life than most of the previously used HRQoL-tools. This may provide useful information for intervention and follow-up in health care.

In conclusion, the British English version of the JAMAR was found to have excellent psychometric properties and it is, thus, a reliable and valid tool for the multidimensional assessment of children with JIA.

**Acknowledgements** We thank all families who participated in the project, the team that prepared and reviewed the forward and backward translations, and all members of PRINTO in United Kingdom. We thank the staff of the PRINTO International Coordinating Centre in Genoa (Italy) and in particular Marco Garrone for the overall coordination of the translation process, Silvia Scala and Elisa Patrone for data collection and quality assurance, Luca Villa, Giuseppe Silvestri and Mariangela Rinaldi for the database development and management and the remaining PRINTO team for data entry. The Principal Investigator of the study was Prof. Angelo Ravelli, MD. The scientific coordinator and study methodologist was Nicolino Ruperto, MD, MPH. The project coordinators were Alessandro Consolaro, MD, PhD, Francesca Bovis, BsA. We also thank Prof. Alberto Martini, PRINTO.
Compliance with ethical standards

Conflict of interest Dr. Anderson, Dr. Davidson and Dr. Martin report funding support from Istituto Giannina Gaslini, Genoa, Italy, for the translation and data collection performed at their sites within the EP-OCA project. Dr. Ruperto has received Grants from BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer, Sobi, during the conduct of the study and personal fees and speaker honorarium from Abbvie, Abblynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol-Myers Squibb, Celgene, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, Roche, Sanofi, Servier and Takeda. Dr. Consolaro and Dr. Bovis have nothing to disclose.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study as per the requirement of the local ethical committee.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S et al (2011) A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol 38(5):938–953
2. Ruperto N, Martini A (2011) Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 96(6):596–601
3. Consolaro A, Ruperto N, Filocamo G, Lanni S, Braccioli G, Garrone M et al (2012) Seeking insights into the EPIdemiology, treatment and Outcome of Childhood Arthritis through a multi-national collaborative effort: Introduction of the EPOCA study. Pediatr Rheumatol Online J 10(1):39
4. Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E et al (2018) Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatol Int. https://doi.org/10.1007/s00296-018-3944-1 (in this issue)
5. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P et al (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25(10):1991–1994
6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392
7. Filocamo G, Szajnbok F, Cespedes-Cruz A, Magni-Manzoni S, Pistorio A, Viola S et al (2007) Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis Rheumatol 57(6):913–920
8. Lovell DJ, Howe S, Shear E, Hartner S, McGirr G, Schulte M et al (1989) Development of a disability measurement tool for juvenile rheumatoid arthritis. The juvenile arthritis functional assessment scale. Arthritis Rheumatol 32:1390–1395
9. Howe S, Levinson J, Shear E, Hartner S, McGirr G, Schulte M et al (1991) Development of a disability measurement tool for juvenile rheumatoid arthritis. The juvenile arthritis functional assessment report for children and their parents. Arthritis Rheumatol 34:873–880
10. Singh G, Athreya BH, Fries JF, Goldsmith DP (1994) Measurement of health status in children with juvenile rheumatoid arthritis. J Rheumatol 21:1146–1153
11. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B et al (2010) Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol 37(7):1534–1541
12. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Stawczynski H (1997) The Juvenile Arthritis Quality of Life Questionnaire—development of a new responsive index for juvenile rheumatoid arthritis and juvenile spondyloarthritides. J Rheumatol 24(4):738–746
13. Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS (2002) The PedsQL (TM) in pediatric rheumatology—validity, reliability, and responsiveness of the pediatric quality of life inventory (TM) generic core scales and rheumatology module. Arthritis Rheumatol 46(3):714–725
14. Landgraf JM, Abetz L, Ware JE (1996) The CHQ user’s manual, 1st edn. The Health Institute, New England Medical Center, Boston
15. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio A, Solaria N et al (2012) Parent and child acceptable symptom state in juvenile idiopathic arthritis. J Rheumatol 39(4):856–863
16. Nunnally JC (1978) Psychometric theory, 2nd edn. McGraw-Hill, New York
17. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martin A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheumatol 40(7):1202–1209
18. Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR (1997) MAP-R for Windows: multitrait/multi-item analysis program—revised user’s guide. Version 1.0 ed. Health Assessment Lab, Boston